novel precision drugs that target the tumor microenvironment
Oncomatryx acquires Austrian company to consolidate its tumour microenvironment drugs
Publicada en el Diario Vasco el 23-05-2023
Basque Country Lehendakari´s visit
Iñigo Urkullu ha visitado la empresa biofarmacéutica Oncomatryx, desarrolladora de tratamientos personalizados para atacar los tumores invasivos Osakidetza, a través de Onkologikoa, formará parte de un ensayo clínico de cáncer con metástasis
“I declare war on cancer stroma”
LAUREANO SIMON, Oncomatryx CEO, declares war on tumor microenvironment. “We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision
Clinical Trial
Published by Deia 2022 – 05 -23
Oncomatryx Capital increase 2022
Published by EXPANSIÓN 2022-03-08 Oncomatryx has carried out a capital increase of 15 million euros to start clinical trials with people with invasive tumors in Spain and the USA.
Bizkaia Impacto Social 2022 Award
Published by El Correo 2022-03-07. Oncomatryx Biopharma, S.L. has been honoured with the 2022 Bizkaia Social Impact Award (Premio Impacto Social 2022) by BBK and EL CORREO at the Sustainable Competitiveness Awards
PEGS Europe Virtual Summit 2020
12 Annual PEGS Europe Virtual Summit 2020 9 Nov – 12 Nov 2020 Myriam Fabre, PhD. (Oncomatryx R&D Director) will attend the virtual conference as a speaker on next Tuesday
Poster Presentation at ESMO 2018 Congress
ESMO 2018 Congress Munich, Germany – 19 Oct – 23 Oct 2018 Myriam Fabre, PhD. (Oncomatryx R&D Director) presents the poster: OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with
Oncomatryx at BIO EUROPE SPRING 2018
Oncomatryx will attend BIO EUROPE SPRING 2018, the essential appointment in biotechnology BIO EUROPE SPRING 2018 March 12-14, 2018 Amsterdam, The Netherlands https://ebdgroup.knect365.com/bioeurope- If you are also attending this event and you would like
Oncomatryx at BIO 2017 (San Diego)
Oncomatryx will attend BIO 2017, the Global Event for Biotechnology.